Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2012. The report details a specific share repurchase transaction executed on March 14, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 350,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,447.5 pence per share; lowest price paid was 1,433.5 pence per share.
- Treasury Holdings (Settled): 512,597,927 shares (9.22% of total issued share capital).
- Treasury Holdings (Including Unsettled): 513,797,927 shares (10.18% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,045,289,662 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 350,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.18% when including unsettled purchases. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase or subscribe for securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (512,597,927 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.18% held in Treasury including unsettled shares) for disclosure threshold assessments.
- Review the price paid per share (1,433.5 to 1,447.5 pence) relative to the market price on March 14, 2012.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and earnings.